Listed by the USPTO as GRABER, JAMES J
Tech Center 1600 • Art Units: 1631 1633
This examiner grants 46% of resolved cases
GRABER, JAMES J is assigned to tech center 1600 and art unit 1631. The profile includes 200 resolved cases, with an allowance rate of 46.5% and a median of 1389 days to allowance. Interview lift is 57.6%, higher than the overall allowance measure.
The listed companies are Duke University, St. Jude Children's Research Hospital Inc., and Janssen Pharmaceuticals Inc. The listed firms are POLSINELLI and DUKE UNIVERSITY, THOMAS | HORSTEMEYER, LLP, and AMSTER, ROTHSTEIN & EBENSTEIN LLP. The interview result supports considering interviews as a meaningful tactic, but the allowance result calls for careful claim and evidence strategy. The median duration indicates that applicants should plan for extended prosecution and preserve continuation options.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18952458 | COMPOSITIONS AND METHODS FOR IMPEDING TRANSCRIPTION OF EXPANDED MICROSATELLITE REPEATS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | Non-Final OA | Janssen Biotech, Inc. |
| 18721743 | NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18953275 | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18367392 | NEURONAL CELL CULTURES AS COMPUTE SUBSTRATES | Final Rejection | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 18289881 | 3D HUMAN DISTAL LUNG ORGANOIDS CONTAINING EPITHELIAL, IMMUNE AND MESENCHYMAL COMPONENTS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18568091 | METHODS FOR ENGINEERING AND USE OF CILIATED ORGANOIDS HAVING NATIVE-LIKE, APICAL-OUT POLARITY | Non-Final OA | Carnegie Mellon University |
| 18294033 | CULTURED ADIPOSE TISSUE | Non-Final OA | Trustees of Tufts College |
| 18248193 | PRODUCTION OF MEGAKARYOCYTES AND PLATELETS IN A CO-CULTURE SYSTEM | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18853458 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18547332 | Compositions For and Methods of Improving Gene Therapy | Non-Final OA | Duke University |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | Final Rejection | DUKE UNIVERSITY |
| 18840303 | MULTIPLEXED REPRESSION OF IMMUNOSUPPRESSIVE GENES | Non-Final OA | Yale University |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | Non-Final OA | VERTEX PHARMACEUTICALS INCORPORATED |
| 17783040 | Method for Preparing CD7-Negative, CD3-Positive T Cells | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18704322 | METHOD FOR PRODUCING ORGANISM, AND METHOD FOR PROMOTING DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED STEM CELLS INTO VASCULAR ENDOTHELIAL CELLS | Final Rejection | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
| 18517402 | METHOD FOR PREPARING BROWN ADIPOCYTE | Final Rejection | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | Non-Final OA | Sana Biotechnology, Inc. |
| 17640711 | GENE EDITING FOR VIRAL INFECTIONS | Final Rejection | THEMBA INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.5% of resolved applications examined by James J Graber were allowed (200 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.
This examiner's interview lift is +57.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by James J Graber took 1,389 days on average from filing to allowance.
James J Graber examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).